The Latest Cardiac and Vascular News
– 44-48% Mean Reductions in LDL-C Achieved on Top of Continued Standard of Care – Phase 3 Planning is Ongoing PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression […]
Only Children with the Most Severe HoFH are Diagnosed Before Adulthood, Putting those Not Identified Early at Risk for Heart Disease at a Young Age Findings presented in poster at AAP National Conference ANAHEIM, Calif.–(BUSINESS WIRE)–The Family Heart Foundation, a leading research and advocacy organization, shared results from an analysis of patients […]
